International Journal for Doctor of Medicine and  Medical Students (IJDMMS)

Abstract

Thyroid cancer is a malignancy of the thyroid gland, a small butterfly-shaped organ located at the base of the neck that regulates metabolism. While generally considered highly treatable with an excellent prognosis, its incidence has risen globally over the last few decades. This article explores the various subtypes of thyroid cancer, their pathological underpinnings, diagnostic protocols, and modern treatment modalities. We further discuss the impact of early detection and the nuances of lifelong medication management.

Keywords: Thyroid Neoplasms, Papillary Carcinoma, Endocrinology, Levothyroxine, Radioactive Iodine, Thyroidectomy.

Introduction

The thyroid gland produces hormones that control heart rate, blood pressure, body temperature, and weight. Thyroid cancer occurs when cells undergo genetic mutations that allow them to grow and multiply rapidly, forming a tumor. Unlike many other cancers, thyroid cancer is often diagnosed in younger adults and is significantly more common in women than in men.

Risk Factors and Complications

Risk Factors:

●       Gender and Age: Women are three times more likely to develop thyroid cancer.

●       Radiation Exposure: Previous radiation treatments to the head and neck.

●       Inherited Genetic Syndromes: Such as Familial Medullary Thyroid Carcinoma (FMTC) or Multiple Endocrine Neoplasia (MEN) type 2.

●       Iodine Deficiency: Low dietary iodine is linked to certain follicular types.

Complications:

●       Metastasis: Spread to lymph nodes, lungs, or bones.

●       Recurrence: Cancer can return years after treatment, even if the thyroid was removed.

●       Vocal Cord Paralysis: The tumor or surgery can damage the laryngeal nerve, causing hoarseness.

Signs and Symptoms

In the early stages, thyroid cancer may not show any symptoms. As it grows, it may cause:

1.     A lump (nodule) that can be felt through the skin on the neck.

2.     A feeling that tight shirt collars are becoming too tight.

3.     Changes to the voice, including increasing hoarseness.

4.     Difficulty swallowing (dysphagia).

5.     Persistent cough not due to a cold.

Types and Pathology

Thyroid cancers are classified based on the type of cell they originate from:

●       Papillary Thyroid Cancer (80%): The most common form; grows slowly and usually responds well to treatment.

●       Follicular Thyroid Cancer (10-15%): Often found in countries with iodine deficiency.

●       Medullary Thyroid Cancer (4%): Develops in C cells that produce calcitonin; often has a genetic component.

●       Anaplastic Thyroid Cancer (1%): Rare, aggressive, and difficult to treat.

Diagnosis and Lab Tests

The diagnostic journey typically involves:

●       Physical Exam: Checking for physical changes in the thyroid.

●       Thyroid Function Tests: Blood tests to check levels of TSH, T3, and T4.

●       Thyroglobulin (Tg): Often used as a tumor marker after surgery.

●       Ultrasound: To determine if a nodule is solid or fluid-filled.

●       Fine-Needle Aspiration (FNA) Biopsy: Removing a small sample of tissue for microscopic examination.

Treatment and Medication

Treatment depends on the type and stage of the cancer.

1. Surgery

●       Thyroidectomy: Removal of all or most of the thyroid gland.

●       Lobectomy: Removal of only one lobe of the thyroid.

2. Radioactive Iodine (RAI) Therapy

Used after surgery to destroy any remaining thyroid tissue or cancer cells.

3. Medication and Dosing

After a thyroidectomy, patients require lifelong Hormone Replacement Therapy.

●       Drug: Levothyroxine (e.g., Synthroid, Tirosint).

●       Dosage: Typically 1.6 mcg/kg of body weight per day.

○       Example: A 70kg adult might start on 112 mcg or 125 mcg daily.

●       Purpose: To replace the hormones the thyroid no longer produces and to suppress TSH (high TSH can stimulate cancer recurrence).

Discussion

The "overdiagnosis" of thyroid cancer is a significant topic in modern medicine. Because of high-resolution ultrasounds, we are finding tiny nodules that might never have caused harm. The medical community is currently debating "active surveillance" (watching instead of operating) for very small, low-risk papillary tumors. This shift aims to reduce the complications associated with surgery and the burden of lifelong medication.

Conclusion

Thyroid cancer remains one of the most survivable malignancies. Success relies on a multidisciplinary approach involving surgeons, oncologists, and endocrinologists. While the diagnosis is daunting, the combination of surgical innovation and precise hormone replacement allows most patients to lead a full, healthy life.

References

1.     American Thyroid Association (ATA). Guidelines for the Management of Thyroid Nodules and Differentiated Thyroid Cancer. (2021). Pages 45-62. Link to ATA

2.     Haugen, B. R., et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid, Vol 26, Issue 1, Pages 1-133. Link to PubMed

3.     National Cancer Institute (NCI). Thyroid Cancer Treatment (PDQ®)–Health Professional Version. (2023). Link to Cancer.gov

4.     Siegel, R. L., Miller, K. D., & Jemal, A. Cancer statistics, 2024. CA: A Cancer Journal for Clinicians, 74(1), 17–48.

5.     Cabanillas, M. E., McFadden, D. G., & Durante, C. Thyroid cancer. The Lancet, 388(10061), 2783–2795.

6.     Sherman, S. I. Thyroid carcinoma. The Lancet, 361(9356), 501–511.

7.     Tuttle, R. M., et al. Controversies, consensus, and collaboration in the use of active surveillance for managing low-risk papillary thyroid cancer. Thyroid, 27(4), 481–485.

8.     Filetti, S., Durante, C., & Hartl, D. Thyroid cancer: ESMO Clinical Practice Guidelines. Annals of Oncology, 30(12), 1856–1883.

9.     Fagin, J. A., & Wells, S. A. Biologic and clinical perspectives on thyroid cancer. New England Journal of Medicine, 375(23), 2307–2319.

10.  Schlumberger, M., et al. Strategies of radioiodine ablation in patients with low-risk thyroid cancer. New England Journal of Medicine, 366(18), 1663–1673.

11.  Pacini, F., et al. Thyroid cancer: ESMO Clinical Recommendations. Annals of Oncology, 21(suppl_5), v214–v219.

12.  Nikiforov, Y. E., & Nikiforova, M. N. Molecular genetics and diagnosis of thyroid cancer. Nature Reviews Endocrinology, 7(10), 569–580.

13.  Dean, D. S., & Gharib, H. Epidemiology of thyroid nodules. Best Practice & Research Clinical Endocrinology & Metabolism, 22(6), 901–911.

14.  Hegedüs, L. Clinical practice: The thyroid nodule. New England Journal of Medicine, 351(17), 1764–1771.

15.  Cooper, D. S., et al. Revised American Thyroid Association management guidelines. Thyroid, 19(11), 1167–1214.

16.  Durante, C., et al. Long-term outcome of active surveillance of papillary thyroid microcarcinoma. JAMA, 313(9), 926–935.

17.  Ito, Y., et al. An observational trial for papillary thyroid microcarcinoma in Japanese patients. World Journal of Surgery, 34(1), 28–35.

18.  Hundahl, S. A., et al. A national cancer data base report on thyroid carcinoma. Cancer, 83(12), 2638–2648.

19.  Robbins, J., et al. Thyroxine suppression therapy in thyroid cancer management. Journal of Clinical Endocrinology & Metabolism, 87(7), 3126–3130.

20.  Brent, G. A. Clinical practice: Graves’ disease and thyroid hormone therapy principles. New England Journal of Medicine, 358(24), 2594–2605.

21.  Brierley, J. D., et al. TNM classification of thyroid tumors. AJCC Cancer Staging Manual, 8th Edition.

22.  De Groot, L. J., et al. Endocrinology Adult and Pediatric, 7th Edition. Elsevier.

23.  Melmed, S., et al. Williams Textbook of Endocrinology, 14th Edition. Elsevier.

24.  NCCN Clinical Practice Guidelines in Oncology: Thyroid Carcinoma (2024). National Comprehensive Cancer Network.

25.  WHO Classification of Tumours Editorial Board. WHO Classification of Tumours of Endocrine Organs, 5th Edition.